End-to-end contract research for peptide drug candidates — from computational sequence design through organ-chip ADME and efficacy testing. No animal models required.
AI-driven peptide sequence generation, cyclization strategy, and stability engineering. Predict half-life, membrane permeability, and aggregation propensity in silico.
Solid-phase and solution-phase synthesis, purification, and full analytical characterization including LC-MS, CD spectroscopy, and thermal stability profiles.
Test peptide candidates on human gut-on-chip (oral bioavailability), liver-chip (metabolism), kidney-chip (clearance), and disease-model chips for target engagement.
Specialized expertise in incretin mimetics, antimicrobial peptides, cell-penetrating peptides, and peptide-drug conjugates. Ride the semaglutide wave with differentiated candidates.